Xeris Biopharma Holdings, Inc. (XERS) Institutional Ownership

Ownership Summary

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has 218 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 55.6% of Xeris Biopharma Holdings's outstanding shares in December 2025, down from 56.1% in September 2025.
• Their total shares held in XERS increased 4.21% quarter over quarter, and separately, investors owning Xeris Biopharma Holdings increased 36.25% from a year ago.
• Of these 218 funds, 111 grew their exposure to Xeris Biopharma Holdings, 74 cut back, and 33 maintained positions.
• Altogether, these fund groups held 98.67Mn shares in XERS by December 2025, up by 3.99Mn shares quarter on quarter, and up 26.39Mn shares year over year.
• BlackRock, Inc. leads ownership in XERS with 12.95Mn shares as of December 31, 2025, equal to 7.29% of outstanding shares.
• Top purchasers of XERS stock for the quarter ending December 2025 included ARMISTICE CAPITAL, LLC (1.91Mn), Parkman Healthcare Partners LLC (1.72Mn), MILLENNIUM MANAGEMENT LLC (1.41Mn), Rosalind Advisors, Inc. (1.12Mn), UBS Group AG (1.04Mn).
• Leading sellers of Xeris Biopharma Holdings shares for the quarter ending December 2025 were DRIEHAUS CAPITAL MANAGEMENT LLC (2.08Mn), Goldman Sachs Group Inc (1.52Mn), Connor, Clark & Lunn Investment Management Ltd. (651.07K), Prudential Financial Inc (561.81K), VOLORIDGE INVESTMENT MANAGEMENT, LLC (441.01K).
• According to Business Quant data, leading holders of XERS for December 2025 are BlackRock, Inc. (12.95Mn), D. E. Shaw & Co., Inc. (7.79Mn), State Street Corp (4.66Mn), GEODE CAPITAL MANAGEMENT, LLC (4.29Mn), Qube Research & Technologies Ltd (4.11Mn), Rosalind Advisors, Inc. (3.23Mn), Nuveen, LLC (2.92Mn), Morgan Stanley (2.57Mn), MILLENNIUM MANAGEMENT LLC (2.27Mn), WELLINGTON MANAGEMENT GROUP LLP (2.17Mn).